Impact of conophylline on the progression in NASH

2023 Fiscal Year Final Research Report

• Project/Area Number: 20K08317
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 53010:Gastroenterology-related
• Research Institution: Aichi Medical University
• Principal Investigator: NAKADE YUKIOMI 愛知医科大学, 愛知医科大学, 客員研究員 (70431400)
• Project Period (FY): 2020-04-01 – 2024-03-31
• Keywords: MASH / コノフィリン / PPARalpha / 高脂肪食 / メタボローム解析

Outline of Final Research Achievements

Conophyllin administration on a high-fat diet suppressed hepatic lipidification, inflammation, and fibrosis induced by a high-fat diet. Transcriptome analysis showed that PPARAmRNA expression was significantly upregulated in the conophylline-treated group with respect to hepatic lipidification compared to the high-fat diet group. Metabolomic analysis of hepatic lipids showed that conophyllin treatment decreased hepatic triglycerides while increasing phosphatidylethanolamine, which has also been reported to be involved in the secretion of VLDL in the liver. The increase in hepatic phosphatidylethanolamine by conophyllin may be involved in the promotion of VLDL secretion.

Translated with DeepL.com (free version)

Free Research Field

肝疾患

Academic Significance and Societal Importance of the Research Achievements

本研究は、高脂肪食によって引き起こされる肝脂肪化やそれに関連する代謝異常の理解を深め、コノフィリンのような低分子化合物が肝機能を改善するための有望な治療法や予防法なる可能性があることに学術的意義があるものと推察される。また肥満やメタボリックシンドロームといった社会的な健康問題に関連する肝臓疾患の予防や治療に将来役立つ可能性があります。